Matches in SemOpenAlex for { <https://semopenalex.org/work/W19361767> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W19361767 endingPage "11" @default.
- W19361767 startingPage "407" @default.
- W19361767 abstract "For topical medications commonly used to treat dermatologic conditions, outcomes may be affected by the choice of delivery vehicles. The aim of this study was to compare quality of life (QOL), effectiveness, user satisfaction, and cost-effectiveness of 2 clobetasol regimens for the treatment of psoriasis over 14 days. In a single-blind design, 32 patients randomized into 2 groups applied either clobetasol foam 0.05% to the skin and scalp or combination clobetasol cream 0.05% to the skin and clobetasol solution 0.05% to the scalp. Psoriasis severity was measured using the standardized Psoriasis Area and Severity Index (PASI) and self-administered PASI (SAPASI). QOL was assessed via the EuroQoL-5D (EQ-5D) questionnaire and Dermatology Life Quality Index (DLQI). Cost-effectiveness was measured by the amount of medication used per body surface area (BSA) treated and by cost per point improvement in PASI score. In this study, a foam formulation performed better than a cream/solution combination by several measures. A greater absolute improvement in psoriasis severity was seen in the group using the foam than in the group using the cream/solution (mean decrease in PASI=5.0 vs 3.3, P=.05). The PASI score in the foam group decreased by 41% versus 35% in the cream/solution group (P=.17). In scalp psoriasis, the group using the foam had greater improvement in both absolute (P=.03) and percentage (P=.03) terms and than the solution group. When measuring global QOL, foam users had a significantly greater increase in EQ-5D than those using the cream/solution in absolute (P=.05, P=.02) and percentage (P=.04, P=.02) terms (first and second survey components, respectively). Differences in improvement of skin-specific QOL, quantified by DLQI scores between groups, were suggested but not statistically significant. Patients using foam spent less time applying medication compared with previous topical medications (P<.001). No significant difference in cost was appreciated between foam and cream/solution over the period after controlling for BSA (8.18 dollars vs 7.05 dollars per percentage BSA affected, P=.30)." @default.
- W19361767 created "2016-06-24" @default.
- W19361767 creator A5026566958 @default.
- W19361767 creator A5039555173 @default.
- W19361767 creator A5087673278 @default.
- W19361767 date "2003-11-01" @default.
- W19361767 modified "2023-09-29" @default.
- W19361767 title "Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis." @default.
- W19361767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14655784" @default.
- W19361767 hasPublicationYear "2003" @default.
- W19361767 type Work @default.
- W19361767 sameAs 19361767 @default.
- W19361767 citedByCount "14" @default.
- W19361767 countsByYear W193617672012 @default.
- W19361767 countsByYear W193617672013 @default.
- W19361767 countsByYear W193617672014 @default.
- W19361767 countsByYear W193617672015 @default.
- W19361767 countsByYear W193617672017 @default.
- W19361767 countsByYear W193617672020 @default.
- W19361767 countsByYear W193617672023 @default.
- W19361767 crossrefType "journal-article" @default.
- W19361767 hasAuthorship W19361767A5026566958 @default.
- W19361767 hasAuthorship W19361767A5039555173 @default.
- W19361767 hasAuthorship W19361767A5087673278 @default.
- W19361767 hasConcept C141071460 @default.
- W19361767 hasConcept C159110408 @default.
- W19361767 hasConcept C16005928 @default.
- W19361767 hasConcept C168563851 @default.
- W19361767 hasConcept C2776110085 @default.
- W19361767 hasConcept C2776173921 @default.
- W19361767 hasConcept C2777011040 @default.
- W19361767 hasConcept C2777501473 @default.
- W19361767 hasConcept C2778515351 @default.
- W19361767 hasConcept C2779951463 @default.
- W19361767 hasConcept C2780564577 @default.
- W19361767 hasConcept C71924100 @default.
- W19361767 hasConceptScore W19361767C141071460 @default.
- W19361767 hasConceptScore W19361767C159110408 @default.
- W19361767 hasConceptScore W19361767C16005928 @default.
- W19361767 hasConceptScore W19361767C168563851 @default.
- W19361767 hasConceptScore W19361767C2776110085 @default.
- W19361767 hasConceptScore W19361767C2776173921 @default.
- W19361767 hasConceptScore W19361767C2777011040 @default.
- W19361767 hasConceptScore W19361767C2777501473 @default.
- W19361767 hasConceptScore W19361767C2778515351 @default.
- W19361767 hasConceptScore W19361767C2779951463 @default.
- W19361767 hasConceptScore W19361767C2780564577 @default.
- W19361767 hasConceptScore W19361767C71924100 @default.
- W19361767 hasIssue "5" @default.
- W19361767 hasLocation W193617671 @default.
- W19361767 hasOpenAccess W19361767 @default.
- W19361767 hasPrimaryLocation W193617671 @default.
- W19361767 hasRelatedWork W1778030670 @default.
- W19361767 hasRelatedWork W19361767 @default.
- W19361767 hasRelatedWork W2766413417 @default.
- W19361767 hasRelatedWork W2911012132 @default.
- W19361767 hasRelatedWork W2943953236 @default.
- W19361767 hasRelatedWork W3084498249 @default.
- W19361767 hasRelatedWork W3187084958 @default.
- W19361767 hasRelatedWork W4205675137 @default.
- W19361767 hasRelatedWork W4245009736 @default.
- W19361767 hasRelatedWork W4252495384 @default.
- W19361767 hasVolume "72" @default.
- W19361767 isParatext "false" @default.
- W19361767 isRetracted "false" @default.
- W19361767 magId "19361767" @default.
- W19361767 workType "article" @default.